REAL WORLD ADHERENCE, PERSISTENCE, RELAPSE AND MULTIPLE SCLEROSIS SYMPTOMS AMONG PATIENTS TREATED WITH ORAL DISEASE-MODIFYING THERAPIES

被引：0
|
作者：
Leist, T. [1 ]
Le, H. [2 ]
Verma, S. [3 ]
Cole, M. [4 ]
Afolabi, M. [3 ]
Tsai, W. L. [3 ]
Keenan, A. [5 ]
机构：
[1] Jefferson Univ, Philadelphia, PA USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] STATinMED Res Inc, Plano, TX USA
[4] Janssen Global Serv LLC, Southampton, PA USA
[5] Janssen Global Serv LLC, Titusville, NJ USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PB3
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [2] Adherence to disease-modifying therapies among patients with multiple sclerosis in Bulgaria - A real world study
    Seitaridou, Yoana
    Chamova, Teodora
    Kamusheva, Maria
    PHARMACIA, 2024, 71 : 1 - 7
  • [3] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    Journal of Neurology, 2017, 264 : 2325 - 2329
  • [4] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
  • [5] Real-world persistence of multiple sclerosis disease-modifying therapies
    Tallantyre, Emma C.
    Dobson, Ruth
    Froud, Joseph L. J.
    St John, Frederika A.
    Anderson, Valerie M.
    Arun, Tarunya
    Buckley, Lauren
    Evangelou, Nikos
    Ford, Helen L.
    Galea, Ian
    George, Sumi
    Gray, Orla M.
    Hibbert, Aimee M.
    Hu, Mo
    Hughes, Stella E.
    Ingram, Gillian
    Kalra, Seema
    Lim, Chia-Hui E.
    Mathews, Joela T. M.
    McDonnell, Gavin V.
    Mescall, Naomi
    Norris, Sam
    Ramsay, Stephen J.
    Rice, Claire M.
    Russell, Melanie J.
    Shawe-Taylor, Marianne J.
    Williams, Thomas E.
    Harding, Katharine E.
    Robertson, Neil P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (07)
  • [6] Real-World Assessment of Adherence and Persistence to Second-Line Disease-Modifying Therapies among Multiple Sclerosis Patients
    Halpern, Rachel
    Agarwal, Sonalee
    Borton, Leigh A.
    Babic, Tomislav
    NEUROLOGY, 2010, 74 (09) : A548 - A549
  • [7] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [8] Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
    Halpern, Rachel
    Agarwal, Sonalee
    Dembek, Carole
    Borton, Leigh
    Lopez-Bresnahan, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 73 - 84
  • [9] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [10] Adherence to disease-modifying therapies in patients with multiple sclerosis
    Koltuniuk, Aleksandra
    Rosinczuk, Joanna
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1557 - 1565
12345